You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD-1 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • transarterial therapies
  • (no location specified)
Nov 27, 2022

Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
Dec 14, 2022

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Melanoma Trial in Beijing (KD6001, Toripalimab)

Not yet recruiting
  • Melanoma
  • Beijing, China
    Beijing Cancer Hospital
Feb 3, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
May 29, 2022

Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 5, 2023

Relapsed or Refractory DLBCL Trial (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Not yet recruiting
  • Relapsed or Refractory DLBCL
  • Anti-PD-1 Antibody Plus Chidamide and Rituximab
  • (no location specified)
Apr 6, 2022

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

Basal Cell Carcinoma Trial in Zürich (Cemiplimab Injection [Libtayo])

Recruiting
  • Basal Cell Carcinoma
  • Cemiplimab Injection [Libtayo]
  • Zürich, Switzerland
    University Hospital Zurich, Clinic of Dermatology
Nov 3, 2022

Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNa Trial in Chongqing (Anti-PD-1 antibody, NAs, Peg-IFNa)

Not yet recruiting
  • Chronic Hepatitis b
  • +2 more
  • Anti-PD-1 antibody
  • +2 more
  • Chongqing, Chongqing, China
    The 2nd affiliated Hospital of Chongqing Medical University
Mar 14, 2023

Chronic Hepatitis b, Anti-PD-1 Antibody Trial in Chongqing (Anti-PD-1 antibody, NAs)

Not yet recruiting
  • Chronic Hepatitis b
  • Anti-PD-1 Antibody
  • Anti-PD-1 antibody
  • NAs
  • Chongqing, Chongqing, China
    The 2nd affiliated Hospital of Chongqing Medical University
Mar 3, 2023

PD-1 Antibody, DC-Cell, NK-Cell Trial (Pembrolizumab, Nivolumab, Sintilimab)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • (no location specified)
Jul 14, 2022

Advanced Malignant Tumors Trial in China (LBL-019 Injection, anti-PD-1 antibody injection)

Recruiting
  • Advanced Malignant Tumors
  • LBL-019 Injection
  • anti-PD-1 antibody injection
  • Wuhan, Hubei, China
  • +4 more
Apr 26, 2022

Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
May 30, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Camrelizumab, US/CT-guided Percutaneous Cryoablation)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 1, 2022

Lenvatinib Combined Anti-PD1 Antibody for Advanced

Completed
  • Hepatocellular Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Jul 8, 2022

Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer Trial in Fairfax (TNG260, Pembrolizumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +6 more
  • Fairfax, Virginia
    NEXT Oncology
Jun 7, 2023

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1

Completed
  • Recurrent Cervical Carcinoma
  • +4 more
  • A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Melanoma (Skin) Trial in Tampa (biological, drug, procedure)

Active, not recruiting
  • Melanoma (Skin)
  • NY-ESO-1 157-165 (165V)
  • +5 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 17, 2023

Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • PD-1 Inhibitors
  • Zhengzhou, Henan, China
    Feng Wang
Oct 9, 2023